NASDAQ:SCYX SCYNEXIS Q2 2026 Earnings Report $4.80 +0.40 (+9.00%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast SCYNEXIS EPS ResultsActual EPS$0.63Consensus EPS -$0.51Beat/MissBeat by +$1.14One Year Ago EPSN/ASCYNEXIS Revenue ResultsActual Revenue$0.24 millionExpected Revenue$0.08 millionBeat/MissBeat by +$155.00 thousandYoY Revenue GrowthN/ASCYNEXIS Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETUpcoming EarningsSCYNEXIS' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SCYNEXIS Earnings HeadlinesSCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.3 hours ago | globenewswire.comSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & DevelopmentSeptember 15, 2026 | globenewswire.com“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen.September 22 at 1:00 AM | Brownstone Research (Ad)SCYNEXIS Names Sanjay Subramanian as CFOSeptember 10, 2026 | finance.yahoo.comScynexis Names Sanjay Subramanian CFOSeptember 10, 2026 | rttnews.comSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial OfficerSeptember 10, 2026 | globenewswire.comSee More SCYNEXIS Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email. Email Address About SCYNEXISSCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing novel antifungal therapies for patients with fungal infections. Its lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal designed to address certain vaginal and other fungal infections. BREXAFEMME was approved by the U.S. Food and Drug Administration in 2021 for the treatment of vulvovaginal candidiasis, commonly known as a yeast infection. The product later received an additional U.S. approval for reducing the incidence of recurrent vulvovaginal candidiasis in adult and post-menarchal adolescent females. Ibrexafungerp belongs to a new class of antifungal agents known as triterpenoid antifungals. SCYNEXIS has historically focused its research and development activities on addressing drug-resistant and difficult-to-treat fungal infections. The company’s commercial activities are primarily centered on the United States, while it has pursued collaborations and licensing arrangements to support the broader development and commercialization of ibrexafungerp.View SCYNEXIS ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
